Venetoclax for elderly AML patients - 101793


Venetoclax for elderly AML patients

VJHemOnc has 1608 videos Subscribe Here

Description: The BCL2 inhibitor venetoclax has shown remarkable response rates in elderly acute myeloid leukemia (AML) patients when used in combination regimens. Speaking at the International Conference on Acute Myeloid Leukemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Mark Levis, MD, PhD, from The Johns Hopkins Hospital, Baltimore, MD, discusses how this, along with allogenic transplantation, has changed the way in which elderly AML patients are now being treated.
Shared By : VJHemOnc
Posted on : 11/29/17
Added : 1 year ago